Loading...
•
Feb 23
Lifecore Biomedical Q3 2025 Earnings Report
Lifecore Biomedical reported a net loss in Q3 2025 while maintaining solid revenue and progressing operationally.
Key Takeaways
Lifecore posted a net loss of $14.8M in Q3 2025 on revenues of $35.2M. The company advanced its growth plans with new customer agreements and monetized unused equipment to strengthen its balance sheet.
Generated $35.2M in revenue, aligned with guidance
Recorded a net loss of $14.8M, impacted by asset disposal
Adjusted EBITDA reached $5.7M, down slightly from last year
Raised $17M from sale of unused high-speed filler
Lifecore Biomedical
Lifecore Biomedical
Forward Guidance
Lifecore reaffirmed its FY2025 outlook, projecting revenue between $126.5M and $130M and Adjusted EBITDA of $19M to $21M.
Positive Outlook
- Reiterated FY2025 revenue guidance
- Maintained Adjusted EBITDA target
- Signed new and expanded customer agreements
- Increased HA manufacturing demand
- Optimized asset utilization through equipment sale
Challenges Ahead
- Continued net losses
- Higher SG&A costs due to stock-based compensation
- Increased interest expense
- Loss on asset disposal impacted earnings
- Gross profit margin declined YoY